Trial reportClinical infectious diseases : an official publication of the Infectious Diseases Society of America2008
Detection of nonnucleoside reverse-transcriptase inhibitor-resistant HIV-1 after discontinuation of virologically suppressive antiretroviral therapy.
Trial report in Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2008. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed.
- Global HIV-1 transmitted drug resistance in the INSIGHT Strategic Timing of AntiRetroviral Treatment (START) trial.HIV medicine · 2015Trial
- Raltegravir versus Efavirenz regimens in treatment-naive HIV-1-infected patients: 96-week efficacy, durability, subgroup, safety, and metabolic analyses.Journal of acquired immune deficiency syndromes (1999) · 2010Trial
- Lower risk of resistance after short-course HAART compared with zidovudine/single-dose nevirapine used for prevention of HIV-1 mother-to-child transmission.Journal of acquired immune deficiency syndromes (1999) · 2009Trial
- The Potential ofNutrients · 2022Review
- Detection of minority drug resistant mutations in Malawian HIV-1 subtype C-positive patients initiating and on first-line antiretroviral therapy.African journal of laboratory medicine · 2018Article
- Article
- Prevalence of Transmitted HIV Drug Resistance Among Recently Infected Persons in San Diego, CA 1996-2013.Journal of acquired immune deficiency syndromes (1999) · 2016Article
- Article
- Global response to HIV: treatment as prevention, or treatment for treatment?Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2014Article
- Antiretroviral treatment interruptions induced by the Kenyan postelection crisis are associated with virological failure.Journal of acquired immune deficiency syndromes (1999) · 2013Article
- Clinical implications of HIV-1 minority variants.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2013Article
- Adherence as a predictor of the development of class-specific resistance mutations: the Swiss HIV Cohort Study.PloS one · 2013Article
- Safety, tolerability, and pharmacokinetic interactions of the antituberculous agent TMC207 (bedaquiline) with efavirenz in healthy volunteers: AIDS Clinical Trials Group Study A5267.Journal of acquired immune deficiency syndromes (1999) · 2012Article
- Article
- Minority variants of drug-resistant HIV.The Journal of infectious diseases · 2010Review
Corrections and comments
- Commented on by
Authors and funding
17 authors.
Funding
Abstract
Using standard and ultrasensitive techniques, we detected nonnucleoside reverse-transcriptase inhibitor-associated resistance mutations in 11 (20%) of 54 subjects who discontinued virologically suppressive nonnucleoside reverse-transcriptase inhibitor-containing antiretroviral therapy. Resistance was detected in 45% and 14% of subjects with a baseline human immunodeficiency virus type 1 RNA level of 51-400 copies/mL and <or=50 copies/mL, respectively. Mutations remained detectable for at least 48 weeks in some subjects.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.